Therapeutic Response

PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Pembrolizumab in patients with Bladder Urothelial Carcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.